CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Exclusion Criteria

• •Anyone involved with the planning and/or conduct of the study.
• •Has participated in another investigational study during the last 6 months.
• •Any concurrent anticancer therapy or received therapy ≤30 days prior to study.
• •Major surgical procedure at the time of study enrollment or within 28 days prior to the first dose of study drug.
• •Have a vascular invasion or extrahepatic tumor.
• •Main portal vein thrombosis present on imaging.
• •Uncontrolled hepatic encephalopathy at time of enrollment. - Ascites within 6 weeks prior to study treatment.
• •Any contraindications for embolization.
• •Has an active infection such as Tuberculosis, HIV, hepatitis B or C.
• •History of another primary malignancy or myeloproliferative disorder.
• •History of leptomeningeal carcinomatosis.
• •History of active primary immunodeficiency.
• •Any unresolved toxicities from previous anticancer therapy.
• •Active or prior documented GI bleeding due to ulcer or esophageal varices bleeding within 6 months.
• •History or current use of immunosuppressive medications within 14 days prior to study medications.
• •Major surgical procedure within 28 days prior to the first dose of IP.
• •Has an active known or suspected autoimmune disease.
• •Patients with hypothyroidism.
• •Any active skin conditions.
• •History of allogenic organ transplantation.
• •Significant heart disease.
• •Patients weighing \< 30 kg.
• •Patients with celiac disease not controlled by diet alone.
• •Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Have received a live vaccine within 30 days prior to study drug.
• •Woman who are pregnant or breastfeeding.
• •Known allergy or hypersensitivity to the study drug.
• •Have received durvalumab, tremelimumab, anti-PD-1, anti-PD-L1 or anti-CTLA-4 in a prior study.
• •Unwilling or unable to follow the study schedule for any reason.